120,285 Shares in Spectranetics Corp (SPNC) Acquired by Capital Fund Management S.A.

Capital Fund Management S.A. acquired a new position in shares of Spectranetics Corp (NASDAQ:SPNC) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 120,285 shares of the medical equipment provider’s stock, valued at approximately $4,619,000. Capital Fund Management S.A. owned about 0.28% of Spectranetics Corp at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the company. New England Private Wealth Advisors LLC lifted its position in shares of Spectranetics Corp by 0.4% during the 1st quarter. New England Private Wealth Advisors LLC now owns 26,497 shares of the medical equipment provider’s stock worth $772,000 after buying an additional 100 shares during the last quarter. Rhumbline Advisers lifted its position in shares of Spectranetics Corp by 0.6% during the 2nd quarter. Rhumbline Advisers now owns 54,223 shares of the medical equipment provider’s stock worth $2,082,000 after buying an additional 303 shares during the last quarter. PEAK6 Investments L.P. lifted its position in shares of Spectranetics Corp by 7.6% during the 1st quarter. PEAK6 Investments L.P. now owns 11,526 shares of the medical equipment provider’s stock worth $336,000 after buying an additional 816 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its position in shares of Spectranetics Corp by 0.5% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 171,443 shares of the medical equipment provider’s stock worth $4,994,000 after buying an additional 889 shares during the last quarter. Finally, Teachers Advisors LLC lifted its position in shares of Spectranetics Corp by 1.3% during the 1st quarter. Teachers Advisors LLC now owns 80,319 shares of the medical equipment provider’s stock worth $2,339,000 after buying an additional 1,018 shares during the last quarter. Institutional investors and hedge funds own 91.95% of the company’s stock.

Spectranetics Corp (NASDAQ SPNC) opened at 38.45 on Tuesday. Spectranetics Corp has a 1-year low of $19.80 and a 1-year high of $38.55. The stock’s 50 day moving average is $37.28 and its 200-day moving average is $30.10.

Spectranetics Corp (NASDAQ:SPNC) last issued its quarterly earnings results on Thursday, August 3rd. The medical equipment provider reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by $0.29. The business had revenue of $74.71 million for the quarter, compared to analyst estimates of $73.82 million. Spectranetics Corp had a negative net margin of 32.93% and a negative return on equity of 194.18%. Spectranetics Corp’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period last year, the business posted ($0.35) earnings per share. Equities research analysts predict that Spectranetics Corp will post ($1.16) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was first posted by Stock Observer and is the property of of Stock Observer. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.thestockobserver.com/2017/09/12/120285-shares-in-spectranetics-corp-spnc-acquired-by-capital-fund-management-s-a.html.

SPNC has been the subject of several recent analyst reports. BidaskClub downgraded shares of Spectranetics Corp from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 12th. Needham & Company LLC reaffirmed a “buy” rating and issued a $38.50 target price on shares of Spectranetics Corp in a report on Wednesday, June 28th. ValuEngine raised shares of Spectranetics Corp from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Canaccord Genuity cut shares of Spectranetics Corp from a “buy” rating to a “hold” rating and lifted their target price for the company from $37.00 to $38.50 in a report on Monday, July 10th. Finally, Royal Bank Of Canada reaffirmed a “hold” rating and issued a $27.00 target price on shares of Spectranetics Corp in a report on Monday, July 24th. Eleven research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $35.36.

Spectranetics Corp Profile

The Spectranetics Corporation develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company’s products are used to cross, prepare and treat arterial blockages in the heart and legs and to manage pacemaker and defibrillator cardiac leads.

Institutional Ownership by Quarter for Spectranetics Corp (NASDAQ:SPNC)

Receive News & Ratings for Spectranetics Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectranetics Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply